Trials / Completed
CompletedNCT01840735
Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-5737 in Subjects With Cystic Fibrosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the safety, tolerability, and pharmacokinetics of a single dose of GS-5737 administered with a 2.8% saline solution vehicle in adult subjects with CF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GS-5737 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2013-07-01
- Completion
- 2013-08-01
- First posted
- 2013-04-26
- Last updated
- 2014-08-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01840735. Inclusion in this directory is not an endorsement.